每周股票复盘：祥生医疗（688358）Q3净利增41.95%

Core Insights - Xiangsheng Medical (688358) has seen its stock price increase by 8.12% this week, closing at 35.27 yuan as of October 24, 2025, with a market capitalization of 3.955 billion yuan [1] Financial Performance - For Q3 2025, Xiangsheng Medical reported revenue of 107 million yuan, a year-on-year decrease of 6.68%. However, net profit attributable to shareholders increased by 41.95% to 24.224 million yuan. The net profit after excluding non-recurring items was 23.141 million yuan, reflecting a 53.63% increase [2][4] - Cumulatively, for the first three quarters, the company generated revenue of 343 million yuan, down 5.27% year-on-year, while net profit attributable to shareholders decreased by 4.56% to 93.921 million yuan. The total profit increased by 63.21%, primarily due to changes in foreign exchange gains and losses [2] Shareholder Changes - As of September 30, 2025, the number of shareholders for Xiangsheng Medical was 6,167, a reduction of 464 shareholders or 7.0% compared to June 30, 2025. The average number of shares held per shareholder increased from 16,900 shares to 18,200 shares, with an average holding value of 598,200 yuan [1][4] Company Announcements - The board of directors approved several resolutions, including the adjustment of the grant price for the 2024 restricted stock incentive plan from 13.50 yuan to 12.50 yuan per share. Additionally, 26 incentive targets were confirmed to be eligible for 100,860 shares of restricted stock. The company also canceled 97,790 shares of unvested restricted stock and set the grant date for the 2025 restricted stock incentive plan on October 23, 2025, awarding 160,000 shares at a price of 16.50 yuan per share [3]